<DOC>
	<DOCNO>NCT00270257</DOCNO>
	<brief_summary>Drug abuse HIV/AIDS serious global health problem . Injection drug use currently major mode transmission HIV many country . The purpose study determine effectiveness drug risk reduction counsel combine either substitution drug treatment buprenorphine/naloxone ( BUP/NX ) short-term detoxification BUP/NX prevent HIV transmission among injection drug user . Participants recruit study China Thailand .</brief_summary>
	<brief_title>Drug Treatment Combined With Drug Risk Reduction Counseling Prevent HIV Infection Death Among Injection Drug Users</brief_title>
	<detailed_description>Effective HIV prevention among injection drug user ( IDUs ) require educate at-risk population HIV transmission risky behavior , provide mean behavior change . Current treatment opiate dependence focus reduce frequency drug use . BUP/NX combination pill currently use treat opiate-dependent individual . This trial evaluate effectiveness two therapy prevent HIV transmission among IDUs . Drug risk reduction counsel combine either long term medication assist treatment ( LT-MAT ) BUP/NX short term medication assist treatment ( ST-MAT ) BUP/NX compare prevent transmission HIV among opiate-dependent individual . This study last 4.5 year . Participants study randomly assign one two treatment arm . Group 1 receive LT-MAT BUP/NX . Group 2 receive ST-MAT BUP/NX . An initial 4-week safety feasibility phase involve first 50 participant site last approximately 30 week . Study visit occur every week include physical exam blood urine collection . The main treatment phase study last 52 week . Participants Group 1 receive BUP/NX tongue , first daily three time week 52 week . Participants assign Group 1 take part BUP/NX reduction phase , occur Weeks 47 52 . Participants Group 2 receive short-term BUP/NX ; dosage length treatment determine investigator . Participants assign Group 2 receive BUP/NX maximum 18 day ; detoxification may repeat Week 26 participant still inject opiate . After Week 4 safety phase Weeks 26 52 overall study , participant complete intervention acceptability assessment . In addition , participant group attend drug risk reduction counsel weekly . After first 12 week , participant return every 4 week 10 counsel session . HIV test , hepatitis C testing , risk assessment , urine test opiates occur screen Weeks 26 , 52 , 78 , 104 , 130 156 . Plasma blood sample store visit . Hepatitis B test occur Week 26 . Participants China attend study visit approximately Week 104 , participant Thailand attend study visit approximately Week 156 . Participants China incarcerate may participate optional substudy , examine withdrawal effect BUP/NX incarceration . Participants agree take part substudy attend one study visit complete questionnaire .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Opioid-Related Disorders</mesh_term>
	<mesh_term>Naloxone</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<mesh_term>Buprenorphine , Naloxone Drug Combination</mesh_term>
	<criteria>HIVuninfected within 28 day enrollment Meets DSMIV criterion opiate dependence Positive urine test opiate Injected opiate least 12 time 28 day prior enrollment , accord selfreport Willing use acceptable form contraception first 12 month study Able provide contact information willing contact study staff necessary Available study visit least 2 year Current treatment methadone , morphine , levoalphaacetylmethadol ( LAAM ) , naltrexone , nalmefene Currently enrol another HIV prevention drug use intervention study Known sensitivity buprenorphine naloxone Requires immediate medical attention dependence alcohol , benzodiazepine , substance . People dependent tobacco exclude . Currently inject drug abuse opiates , twice last 28 day , accord selfreport Psychological disturbance cognitive impairment may interfere study Acute chronic kidney failure Certain abnormal laboratory value Any medical psychiatric condition , opinion investigator , would make participation study unsafe Pregnant breastfeeding Inclusion Criteria Substudy : Current former participant HPTN 058 study Xinjiang actively longterm treatment arm stable maintenance dose Suboxone detained/arrested ( last dose within 2 day incarceration ) , result immediate cessation Suboxone without taper Currently release detention Willing complete onetime questionnaire Willing sign inform consent Exclusion Criteria Substudy : Any medical psychiatric condition , opinion investigator , would make participation study unsafe , would otherwise interfere study objective interpretation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>HIV Seronegativity</keyword>
	<keyword>Opiate Addiction</keyword>
	<keyword>Opiate Dependence</keyword>
</DOC>